Navigation Links
Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH
Date:12/9/2008

itional clinical indications, and is pursuing development of other antibody product candidates in early stages of development. This press release

and further information about Alexion Pharmaceuticals, Inc. can be found at: www.alexionpharm.com.


    [ALXN-G]

Safe Harbor Statement

This news release contains forward-looking statements, including statements related to potential health and medical benefits from Soliris. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ from those expected, including for example, decisions of regulatory authorities regarding marketing approval or material limitations on the marketing of Soliris, delays in arranging satisfactory manufacturing capability and establishing commercial infrastructure, delays in developing or adverse changes in commercial relationships, the possibility that results of clinical trials are not predictive of safety and efficacy results of Soliris in broader patient populations, the possibility that initial results of commercialization are not predictive of future rates of adoption of Soliris, the risk that third parties won't agree to license any necessary intellectual property to Alexion on reasonable terms or at all, the risk that third party payors will not reimburse for the use of Soliris at acceptable rates or at all, the risk that estimates regarding the number of PNH patients are inaccurate, the risk that pending litigation may be resolved adversely, and a variety of other risks set forth from time to time in Alexion's filings with the Securities and Exchange Commission, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the period ended September 30, 2008 and in Alexion's other filings with the Securities and Exchange Commission. Alexion does not intend to update any of thes
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Alexions Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product
2. Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
3. Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
6. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
7. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
8. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
9. PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
10. NIST studies how new helium ion microscope measures up
11. SpectraCell Laboratories Now Measures Vitamin C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... -- Research and Markets ( ... PharmaBiotech,s new report "Biomarkers - Technologies, Markets ... This report follows the broad definition of a ... measured and evaluated as an indicator of normal ... responses to a therapeutic intervention. Tests based on ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, Inc., ... in the multicenter Phase 2 clinical trial of ... treatment of recurrent subfoveal choroidal neovascularization secondary to ... a unique vascular endothelial growth factor (VEGF) receptor ... "This landmark proof-of-concept study will evaluate ...
(Date:9/2/2015)... ZIONA, Israel , September 2, 2015 ... BVXV) today announced the intent of the National Institute of ... Institutes of Health (NIH) within the Department of Health and ... to be held in the United States ... use of BiondVax,s universal flu vaccine candidate, Multimeric-001 (M-001), as ...
(Date:9/2/2015)... ... September 02, 2015 , ... The TS5-Q is ... commercial video content, to analysis of athletic performance. Producing high-resolution slow-motion video ... too quickly to process with the naked eye. , Slow motion sequences ...
Breaking Biology Technology:Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3
... (NASDAQ: IDIX ), a biopharmaceutical company engaged ... treatment of human viral diseases, today announced the advancement ... IDX719: NS5A Program Idenix announced today ... the Company,s NS5A inhibitor, IDX719. The first part of ...
... FRANCISCO, January 9, 2012 SFJ Pharma ... announced today that it has entered into a collaborative ... 3 clinical trial in Asia of Pfizer,s investigational agent ... risk of recurrent renal cell carcinoma (RCC) following nephrectomy. ...
... SQNM ), a life sciences company providing innovative ... performance and accomplishments, as well as preliminary activities and goals ... Initial 2011 Performance Results , Total revenue ... , Over 21,000 total prenatal and retinal diagnostic tests were ...
Cached Biology Technology:Idenix Reports Advancement of HCV Development Pipeline 2Idenix Reports Advancement of HCV Development Pipeline 3Idenix Reports Advancement of HCV Development Pipeline 4SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma 2Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook 2Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook 3Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook 4
(Date:8/31/2015)... 31, 2015 Research and Markets ( http://www.researchandmarkets.com/research/st5b3m/saudi_arabia ... Arabia Biomedical Sensors Market - Growth, Trends & Forecasts ... The Saudi Arabia Biomedical Sensors market is estimated at ... over the period 2014-2020 The near future ... genetic formulation of each individual. These sensors can be ...
(Date:8/26/2015)... 26, 2015 The report "Multi-Factor Authentication ... Factor), Application (Travel & Immigration, Government, Banking, Defense, Commercial ... to 2020", published by MarketsandMarkets, Multi-Factor Authentication Market is ... at a CAGR of 17.7% between 2015 and 2020. ... igures spread through 169 P ...
(Date:8/24/2015)... , August 24, 2015 The consulting ... ,s largest biometrics manufacturer DERMALOG and its customized solutions and ... African Biometrics Company of the Year Award". DERMALOG is particularly ... .   -Cross reference: Picture is available ... - On Thursday evening, in South ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3
... panobinostat is able to target and destroy triple negative ... Central,s open access journal Breast Cancer Research . ... that panobinostat was able to destroy breast cancer cells ... of breast cancers are found at diagnosis to be ...
... N.Y. -- A pioneering study to gauge the toxicity of ... be safe over a one-year period, a hopeful outcome for ... cancer through nanomedicine. , The research, which will appear on ... the first to test the safety of quantum dots in ...
... The rate at which the rabies virus evolves in ... hosts, according to researchers at the University of Georgia, the ... Leuven in Belgium. Their study, published May 17 in the ... location was the most accurate predictor of the viral rate ...
Cached Biology News:Blocking DNA: HDAC inhibitor targets triple negative breast cancer 2Good news for nanomedicine: Quantum dots appear safe in pioneering study on primates 2Hitting snooze on the molecular clock: Rabies evolves slower in hibernating bats 2Hitting snooze on the molecular clock: Rabies evolves slower in hibernating bats 3
V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Monoclonal Anti-Cystatin A tissue culture supernatant Solution containing 15 mM sodium azide human cystatin A ...
...
... Building on the ease of use and flexibility of ... Biosciences introduces the BDTM LSR II. The BD ... before in a benchtop analyzer. Free up your ... a UV laser to the BD LSR II. The ...
Biology Products: